Mandate

Vinge advises SBB in connection with its sale to Brookfield

Vinge advises Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with its sale of stake in its social infrastructure portfolio for public education to Brookfield for SEK 9.2 billion. The transaction also includes earn out payments up to SEK 1.2 billion.

SBB contributes its SEK 44.9 billion social infrastructure portfolio for public education to a newly formed SBB subsidiary EduCo AB (“EduCo”). Brookfield, one of the world’s largest infrastructure investors, through its open-ended core infrastructure fund (Brookfield Super-Core Infrastructure Partners), acquires a 49% minority stake in EduCo from SBB for approx. SEK 9.2 billion in cash up front, plus up to approx. SEK 1.2 billion in cash through earn-outs. EduCo will be operated and managed by SBB through an asset management agreement with respect to the management of the EduCo portfolio in its entirety.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl and Joel Wahlberg (Capital markets and Public M&A), Niclas Winnberg, Karolina Cohrs, Frida Ställborn, Kristoffer Larsson and Anette Kahn (Real Estate and Social Infrastructure), Albert Wållgren, Linn Adelwald and Axel Jansson (Financing), Maria Dahlin Kolvik and Sebastian Saadieh (M&A), Marcus Glader and Trine Osen Bergqvist (Competition and Regulatory) and Robert Wikholm (Restructuring and Insolvency).

 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026